Compare Invesco WilderHill Clean Energy ETF (PBW) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco WilderHill Clean Energy ETF vs ResMed Inc. — how do they compare? Invesco WilderHill Clean Energy ETF trades at $31.99, while ResMed Inc. trades at $219.5 (market cap $31.73B). The key difference: ResMed Inc. pays a 1.2% dividend while Invesco WilderHill Clean Energy ETF pays none. Which is the better fit depends on your goals.
| PBW | RMD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $283.28 |
52-Week Low | $24.75 | $182.82 |
Market Cap | — | $31.73B |
Enterprise Value | — | $31.08B |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PBW (Invesco WilderHill Clean Energy ETF) trades at $32.38, up 1.86% today, but technical indicators show a bearish trend with moving averages signaling selling pressure. The ETF's unique selection criteria focusing on ecological factors over financial metrics creates an undiversified portfolio that has underperformed broader markets. Recent market volatility from geopolitical tensions and tech sector sell-offs has impacted clean energy ETFs despite long-term growth catalysts.
The clean energy sector faces near-term headwinds from market volatility, though long-term prospects remain supported by global energy security concerns and substantial international investment. PBW's performance remains tied to clean energy adoption trends and policy developments, with current technical weakness suggesting cautious near-term positioning.
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco WilderHill Clean Energy ETF
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
